Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADAR
2022-500031-37-00Phase 3Authorised
- Sponsor
- University College London
- Start
- Jul 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised trial of brentuximab vedotin, doxorubicin, bleomycin, vinblastine and dacarbazine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by University College London. Primary endpoint: Progression-Free Survival. Planned start Jul 2023; status: authorised.
02
Drugs
brentuximab vedotindoxorubicinbleomycinvinblastinedacarbazine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2022-500031-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500031-37-00.